AMERICAN GLAUCOMA SOCIETY FOUNDATION

INVESTING IN PATIENT CARE, INNOVATION, AND DISCOVERY.

2018 ANNUAL REPORT





OUR MISSION

The American Glaucoma Society Foundation's Mission is to support glaucoma research and education, and to promote excellence in the care of patients with glaucoma.

Thank you for your partnership with the American Glaucoma Society Foundation.

It is a pleasure to present our 2018 Annual Report that highlights the programs we support to further glaucoma research, patient care, and mentoring of our young physician scientist to one day find a cure for this silent thief of vision.

AMERICAN GLAUCOMA SOCIETY
CARES

Sadly, there are millions of people worldwide living with the threat of impending blindness from glaucoma. As the population ages and growing numbers are afflicted with glaucoma, the AGSF's mission becomes increasingly vital.

AGS Cares is a public service program dedicated to providing surgical glaucoma care to uninsured patients at no cost to those who qualify through a national network of volunteer glaucoma specialists. The program launched late 2017 and we are proud to announce that we have over 50 volunteer physicians to support this program, and helped several patients by providing financial aid for very much needed glaucoma surgery. We look forward to growing this program to continue helping those in need.

Together, we can help change lives.

AMERICAN GLAUCOMA SOCIETY FOUNDATION

INVESTING IN PATIENT CARE, INNOVATION, AND DISCOVERY.

During 2018, the American Glaucoma Society Foundation has made great strides toward advancement of our mission in support of glaucoma research and education, and to promote excellence in the care of patients with glaucoma. We are delighted to announce that the AGS Foundation has continued to support AGS programs in 2018.

AGS Cares

Formally launched at the AGS 2017 Annual Meeting, this public-service program dedicated to providing surgical glaucoma care to uninsured patients at no cost to those who qualify through a national network of volunteer glaucoma specialists.

AGS Clinician Scientist Research Grants for Young Clinician Scientist

Encourages the development of young clinician scientists in glaucoma by providing funding for research projects within the first 5 years after fellowship completion, a time critical for developing the skills necessary for a research career and establishing a track record of productivity.

Mentoring for the Advancement of Physician Scientists (MAPS)

A multi-faceted mentoring program created to fulfill the mission of the AGS by supporting early career glaucoma specialists and scientists by providing tools and resources to further their careers as potential leaders in the science, research, and specialty glaucoma care.

Patient Reported Outcome Measurement for Minimally Invasive Glaucoma Surgery (PROM for MIGS)

A Patient Related Outcome (PRO) questionnaire is being developed specifically for patients undergoing MIGS surgery; however, the tool may be more generally useful for other studies in subjects with mild to moderate glaucoma. The AGS and AGSF are committed to making this tool available, without cost, to anyone who wishes to use it to advance our understanding and treatment of glaucomatous disease.

FDA Collaboration

Provides an ideal platform for physicians, researchers, and FDA colleagues to develop the regulatory science that guides the advancement and approval of new glaucoma diagnostic technologies and surgical devices. Several workshops have been conducted in the past. The AGS continues to strengthen its collaboration with the FDA.

AGS Core Lecture Series

This comprehensive educational program is scheduled to launch in 2019–2020 to encompass the fundamentals of glaucoma pathogenesis, diagnosis, and treatment. The content will be accessible to all AGS members.

The AGS will celebrate its 30th Annual Scientific Meeting February 27 – March 1, 2020 in Washington, DC where we proudly recognize Richard K. Parrish as our Guests of Honor. Colleagues from the United States, Canada, and abroad are invited to attend presentations on innovative research findings, novel surgical approaches, and participate in in-depth symposia – all directed to advance the care of glaucoma patients.

The American Glaucoma Society Foundation is most grateful for the generous support we have received from our patients, colleagues, and industry partners. Thank you once again for joining us in our mission to prevent vision loss from glaucoma by investing in patient care, innovation, and discovery.

Dale K. Heuer, MD
President, American Glaucoma Society

AGS 2020 ANNUAL MEETING

YOUNG CLINICIAN SCIENTIST RESEARCH AWARDS

Encourages the development of young clinician scientists in glaucoma by providing funding for research projects within the first 5 years after graduation, a time period critical for developing the skills necessary for a research career and establishing a track record of productivity. With generous support from Allergan, Bausch + Lomb, and the American Glaucoma Society. The Foundation supports $40,000 research grant awards to Young Clinician Scientists.

2018 YOUNG CLINICIAN SCIENTIST RECIPIENTS

Grace M. Richter, MD, MPH

USC Roski Eye Institute, Keck School of Medicine of University of Southern California

Detecting Retinal Microcirculation Changes after Intraocular Pressure Reduction in Glaucoma

Qi N. Cui, MD, PhD

Scheie Eye Institute, University of Pennsylvania

Mitochondrial Respiratory Chain Dysfunction in Primary Open Angle Glaucoma

Brian Song, MD

Massachusetts Eye and Ear Infirmary, Harvard Medical School

Glaucoma Detection in Diabetes Teleretinal Programs

Nathaniel C. Sears, MD

Department of Ophthalmology and Visual Sciences, University of Iowa

Making and Characterizing a Hybrid Genetic / Experimental Mouse Model of Glaucoma

MENTORING FOR THE ADVANCEMENT OF PHYSICIAN SCIENTISTS (MAPS)

A multi-faceted mentoring program fulfills the mission of the AGS by supporting early career glaucoma specialists and scientists by providing tools and resources to further their careers as potential leaders in the science, research and the specialty of glaucoma care. The MAPS awards program was first initiated in 2007 and generously funded by Allergan. Today, Allergan is a prominent supporter of the program along with generous support from Cure Glaucoma Foundation and private donors.

2018 MAPS AWARDS RECIPIENTS

Eva DeVience, MD

West Virginia University Eye Institute

Evaluation of Icare Home for Self-Tonometry by Glaucoma Patients

Mona A. Kaleem, MD

University of Maryland School of Medicine

Characteristics of Glaucoma Patients Attending Vision Rehabilitation

Mohamed S. Sayed, MD

Bascom Palmer Eye Institute, University of Miami Miller School of Medicine

Machine Learning Algorithm for Glaucoma Visual Field Analysis

Jithin Yohannan, MD, MPH

Johns Hopkins Wilmer Eye Institute

Evidence Based Criteria for Assessment of Optic Nerve OCT Reliability

Jiun L. Do, MD, PhD

University of California San Diego

Cellular Replacement Strategies to Restore Visual Function

Ken Lin, MD, PhD

Gavin Herbert Eye Institute, University of California, Irvine

Identifying Risk Factors for Glaucoma Tube Shunt Surgery using Machine and Deep Learning

Qianqian Wang, MD, FRCSC

University of Montreal Hospital Centre

Longitudinal Vascular and Neurosensory Alterations following Intraocular Pressure elevation in mice"

Nazlee Zebardast, MD, MSC

Massachusetts Eye and Ear

Understanding Progression in Angle Closure Eyes

Joshua Ehrlich, MD

Regents of the University of Michigan

Validation of a Performance-Based Outcome Measure for Glaucoma in India

Gavin Roddy, MD, PhD

Mayo Clinic

Stanniocalcin-1 Treatment of the DBA/2J Mouse

Benjamin Xu, MD, PhD

University of Southern California

Automated Detection of Gonioscopic Angle Closure Based on Anterior Segment OCT Imaging

EDUCATION

FDA, ANSI & AGS COLLABORATION

Provides an ideal platform for physicians, researchers and regulatory agencies to develop the regulatory science that guides the advancement and approval of new glaucoma diagnostic technologies and surgical devices. Several workshops have been conducted in the past. The AGS continues to strengthen its partnership with the FDA.

PATIENT REPORTED OUTCOME TOOL

The AGS is collaborating with the FDA, Johns Hopkins, Wills Eye Hospital, and Stanford researchers on a project to examine the safety, efficacy, and impact of minimally invasive glaucoma surgery on patient quality of life. We look forward to continuing support for the completion of this tool to measure patient reported outcomes in “MIGS”.

FINANCIAL REPORT

On behalf of the American Glaucoma Society Foundation, I would like to express our sincere gratitude and appreciation for all the generous support we received for the Foundation in 2018, and we look to your much-needed continued support in the years to come.

Over the past year, the AGS Foundation Board Members and Advisory Board members have been hard at work collaborating with the American Glaucoma Society to support our mission to help nurture glaucoma research and education, and to promote excellence in the care of glaucoma patients.

In the coming year, the AGS Foundation will experience significant growth in cultivating the development of new programs for the American Glaucoma Society with continued focus on research, education and patient care. We eagerly look forward to your continued support, and together we will make giant strides in making a difference!



Ronald L. Gross, MD
Treasurer,
American Glaucoma Society Foundation

REVENUE AND SUPPORT			
	Without Donor Restrictions	With Donor Restrictions	Total
Contributions and Grants	59,516	245,000	304,516
Net Assets Released from Restrictions	195,000	(195,000)	
Total Revenue and Support	254,516	50,000	304,516

EXPENSES			
Organizational Support	37,518		37,518
Research Grants	80,000		80,000
MAPS	115,000		115,000
Total Expenses	232,518		232,518

Changes in Net Assets from Operations	21,998	50,000	71,998
Investment Income	1,166		1,166
Net realized and unrealized (loss) gain on investments	(3,060)		(3,060)
Change in net assets	20,104	50,000	70,104
Net assets, beginning of year	201,925	90,000	291,925
Net Assets, end of year	**$222,029.00**	**$140,000.00**	**$362,029.00**

THANK YOU

We express our deepest appreciation to all our donors. Each, and every donation is essential to help us with forwarding our mission.

VISIONARY
$100,000–499,999

Allergan, Inc

BENEFACTOR
$40,000–99,999

Glaukos Corporation

FOUNDER
$10,000–39,999

New World Medical, Inc

ADVOCATE
$5,000–9,999

Cure Glaucoma

David E. I. Pyott

Strobis Glaucoma Foundation, Inc

FRIEND
$1,000–4,999

John W. Bell

Dr. and Mrs. Louis B. Cantor

Boston Eye Surgery & Laser Center

David G. Campbell, MD

Ronald Leigh Fellman, MD

Brian E. Flowers, MD

Chandler Grant Glaucoma Society

Glaucoma Associates of Texas, PA

Dale K. Heuer, MD

Richard A. Lewis, MD

Cynthia Mattox, MD

Felipe A. Medeiros, MD, PhD

Mildred M. G. Olivier, MD

Ophthalmic Consultants of Boston

Arthur L. Schwartz, MD

Marvin L. Sears, MD (in honor of M. Bruce Shields, MD)

M. Bruce Shields, MD

Gregory L. Skuta, MD

William & Martha Slavin

Jonathan H. Talamo, MD

Robert N. Weinreb, MD

SUPPORTER
$10–999

Anonymous

Ann S. Beaver

Elizabeth Benson

Anjali Bhorade, MD

Steven V. L. Brown, MD

Joseph Bulgarini & Sharon Maroldi

Claude F. Burgoyne, MD

Dean W. Carlson, MD

Paul R. Cotran, MD

Domenic M. Falco, DO

Fidelity Charitable

Barbara Fleischer

David Fleischman, MD, MS

Steven J. Gedde, MD

Arlene Goodwich Charitable Fund

David S. Greenfield, MD

Robert J. Griffiths

Ronald L. Gross, MD

Jennifer Hancock

Linda Hill

H. Dunbar Hoskins Jr., MD, FACS

Raul R. Johnson

Paul Harold Kalina, MD

Arthur Keegan

Shan C. Lin, MD

Tim Losch & Brandi Brooks

Nalini A. Madiwale, MD

Nancy McLaughlin

Richard P. Mills, MD, MPH

Aretha Miller

Richard Moeller

Kelly W. Muir, MD

My Tribute Gift Foundation

Alexander Needleman

Network for Good

Deborah Nysather

David J. Palmer, MD

James J. Pasternack, MD

Tania Paul, MD, FRCSC

Louis R. Pasquale, MD

Alan L. Robin, MD

Lisa Fran Rosenberg, MD

Susan H. K. Ryu, MD

Jessie Sanders

Schwab Charitable

Carla J. Siegfried, MD

Alan Silverblatt

Silver Lake Association

Kuldev & Angele Singh

Enitan A. Sogbesan, FACS, FRCSC, MD

Robert L. Stamper, MD

Joshua Stein & Cris Coren

Carolyn Vanderberg

Martin Wand, MD

Deborah Y. Wilson-Umanzor, MD

Rhonda Weinstein

Howard S. Weiss, MD

Yost Construction

Gary Zenz

STOCK TALK

"The meaning of life is to find your gift.
The purpose of life is to give it away."

—Pablo Picasso

Like many American Glaucoma Society members and friends, Dr. Supporter owns stock. In addition to the doctor's professionally managed retirement accounts, the doctor has a separate investment account at a discount brokerage firm. This account includes a variety of mutual funds and individual stocks. Periodically, Dr. Supporter reviews the portfolio to see which securities are increasing in value and which ones are declining. Some of the holdings have appreciated nicely over the years.

Being charitably minded toward the doctor's favorite nonprofit organizations, Dr. Supporter will occasionally arrange to transfer some of their more highly appreciated stocks (10 shares of Apple stock purchased in 1980 at a cost basis of $22 per share) to the AGS Foundation. The AGS Foundation in turn quickly liquidates the stock and uses the cash for the Society's important, tax-exempt purposes. Because the Society's Foundation is a qualified 501c3 charity, it is not required to pay capital gains tax on the sale of the appreciated stock, which was worth $220 when received. Therefore, the gift totaled $2,200 to the AGS Foundation and Dr. Supporter avoided paying the capital gains tax on the nearly $2,000 of total appreciation.

Were Dr. Supporter to sell the stock and give the AGS Foundation the cash directly, the doctor would unnecessarily incur capital gains tax on the amount of appreciation, and thus reduce the cash value of the stock. The gift would actually cost more than the value of a cash gift. Except when a stock has depreciated, it is usually prudent to give the stock to the AGS Foundation and let the foundation sell it to benefit the donor by avoiding unnecessary tax consequences but allowing you to achieve a potentially sizable deduction on federal and perhaps state taxes.

In making the stock gift to the American Glaucoma Society, Dr. Supporter also receives an income tax charitable deduction for the full value of the gift at the time of its sale, which the doctor can apply against a percentage of the doctor's adjusted gross income.

Giving shares of stock to the AGS Foundation is really quite easy. It can be done with a letter to your brokerage firm, instructing them to transfer or "journal" a particular number of shares of publicly traded stock to the American Glaucoma Society Foundation account.

For more information about making charitable gifts with stock and potential advantages to you, please feel free to call me at 415-561-8587 or email me at kboyden@ags-foundation.org.

Thank you for your considered support.

Ken Boyden

Ken Boyden, Esquire
Chief Philanthropy Officer
American Glaucoma Society Foundation

AMERICAN GLAUCOMA SOCIETY FOUNDATION

INVESTING IN PATIENT CARE, INNOVATION, AND DISCOVERY.

MAKE A DONATION

The American Glaucoma Society Foundation is a 501(c)3 non-profit organization. Donations are tax-deductible as provided by law.

We accept checks payable to:

American Glaucoma Society Foundation
655 Beach Street
San Francisco, CA 94109

2018 AMERICAN GLAUCOMA SOCIETY FOUNDATION BOARD OF DIRECTORS

Cynthia Mattox, MD
President

Dale K. Heuer, MD
Vice President

Ronald L. Fellman, MD
Secretary

Ronald L. Gross, MD
Treasurer

Steven J. Gedde, MD

Anjali Bhorade, MD

Brian E. Flowers, MD

Brian A. Francis, MD

David S. Greenfield, MD

Paul P. Lee, MD, JD

Kelly W. Muir, MD

Mildred M.G. Olivier, MD

Louis R. Pasquale, MD

Alan L. Robin, MD

Carla J. Siegfried, MD

Kuldev Singh, MD, MPH

Joshua D. Stein, MD, MS

Gregory L. Skuta, MD

Robert N. Weinreb, MD

2019 AMERICAN GLAUCOMA SOCIETY FOUNDATION BOARD OF DIRECTORS

Dale K. Heuer, MD
President

Donald L. Budenz, MD, MPH
Vice President

Ronald L. Fellman, MD
Secretary

Ronald L. Gross, MD
Treasurer

James D. Brandt, MD

Louis B. Cantor, MD

Brian E. Flowers, MD

Brian A. Francis, MD

Steven J. Gedde, MD

David S. Greenfield, MD

Richard K. Lee, MD

Cynthia Mattox, MD

Felipe A. Medeiros, MD, PhD

Kelly W. Muir, MD

Paula Anne Newman-Casey, MD

Lisa Fran Rosenberg, MD

Joel S. Schuman, MD

Carla J. Siegfried, MD

Kuldev Singh, MD, MPH

Joshua D. Stein, MD, MS

AMERICAN GLAUCOMA SOCIETY FOUNDATION EXECUTIVE STAFF

Alan L. Robin, MD
Executive Vice President

Ken Boyden, JD, EdD
Chief Philanthropy Officer

AMERICAN GLAUCOMA SOCIETY FOUNDATION ADVISORY BOARD

Louis B. Cantor, MD
Chair

Vicente Anido, Jr., PHD

Thomas W. Burns

Gerald D Cagle, PHD

Jimmy Cliff

Roger Mason, Jr.

Jim Mazzo

Mildred M. G. Olivier, MD

David E. I. Pyott

Calvin W. Roberts, MD

Brent L. Saunders, MBA, JD

Arthur L. Schwartz, MD

Alfred Sommer, MD, MHS

George L. Spaeth, MD

Jonathan H. Talamo, MD

Robert N. Weinreb, MD